Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Chaiwat Ngampiyasakul"'
Autor:
Payal B. Patel, Andrew Belden, Ryan Handoko, Thanyawee Puthanakit, Stephen Kerr, Pope Kosalaraksa, Pradthana Ounchanum, Suparat Kanjanavanit, Linda Aurpibul, Chaiwat Ngampiyasakul, Wicharn Luesomboon, Claude A. Mellins, Kathleen Malee, Jintanat Ananworanich, Robert Paul
Publikováno v:
Cambridge Prisms: Global Mental Health, Vol 8 (2021)
Abstract Background Cognitive and behavioral impairment are common in children living with perinatally acquired HIV (pHIV) and children exposed to HIV in utero but uninfected (HEU). Methods We sought to determine the prevalence of adverse behavioral
Externí odkaz:
https://doaj.org/article/7475f464887e433bb77a409d1d7c15df
Autor:
Wicharn Luesomboon, Claude A. Mellins, Kathleen Malee, Stephen J. Kerr, Payal B. Patel, S. Kanjanavanit, Linda Aurpibul, Pope Kosalaraksa, Jintanat Ananworanich, Ryan Handoko, Robert H. Paul, Pradthana Ounchanum, Chaiwat Ngampiyasakul, Thanyawee Puthanakit, Andrew C. Belden
Publikováno v:
Global Mental Health
Background Cognitive and behavioral impairment are common in children living with perinatally acquired HIV (pHIV) and children exposed to HIV in utero but uninfected (HEU). Methods We sought to determine the prevalence of adverse behavioral symptomat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86b6ff60e614dbcdb00eeab6f1d315c4
http://europepmc.org/articles/PMC8127634
http://europepmc.org/articles/PMC8127634
Autor:
Sophie Le Coeur, Pornchai Technakunakorn, Nicole Ngo-Giang-Huong, Chaiwat Ngampiyasakul, Marc Lallemant, Shabbar Jaffar, Suparat Kanjanavanit, Intira Jeannie Collins, Somboon Sriminiphant, Suchat Hongsiriwon, Gonzague Jourdain, Treatment Study Team, Rawiwan Hansudewechakul, Trinh Duong
Publikováno v:
Clinical Infectious Diseases. 51:1449-1457
Background. There are scarce data on the long-termsurvival of human immunodeficiency virus (HIV)—infected children receiving antiretroviral therapy (ART) in lower-middle income countries beyond 2 years of follow-up. Methods. Previously untreated ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f09394d8501cdb042708d040811ad00c
https://doi.org/10.1086/657401
https://doi.org/10.1086/657401
Autor:
Clare Shakeshaft, Carlo Giaquinto, Tim R. Cressey, Adeodata Kekitiinwa, David M. Burger, Pauline Amuge, Pablo Rojo, Cecilia L. Moore, Osee Behuhuma, Yacine Saϊdi, Linda Barlow-Mosha, James Hakim, Alexandra Compagnucci, Lorna Atwine, Diana M. Gibb, Ebrahim Variava, Hilda Mujuru, Mark F. Cotton, Victor Musiime, Moherndran Archary, Deborah Ford, Cissy Kityo, Thanyawee Puthanakit, Anna Turkova, Avy Violari, Abbas Lugemwa
Publikováno v:
BMC Infectious Diseases, 21
BMC Infectious Diseases
BMC Infectious Diseases, 2021, 21 (1), pp.5. ⟨10.1186/s12879-020-05672-6⟩
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-14 (2021)
BMC Infectious Diseases, BioMed Central, 2021, 21 (1), pp.5. ⟨10.1186/s12879-020-05672-6⟩
BMC Infectious Diseases, 21, 1
BMC Infectious Diseases
BMC Infectious Diseases, 2021, 21 (1), pp.5. ⟨10.1186/s12879-020-05672-6⟩
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-14 (2021)
BMC Infectious Diseases, BioMed Central, 2021, 21 (1), pp.5. ⟨10.1186/s12879-020-05672-6⟩
BMC Infectious Diseases, 21, 1
Background Dolutegravir (DTG)-based antiretroviral therapy (ART) is highly effective and well-tolerated in adults and is rapidly being adopted globally. We describe the design of the ODYSSEY trial which evaluates the efficacy and safety of DTG-based
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dc6d69b5f99a118685712a7a9aa09f7
http://hdl.handle.net/2066/232479
http://hdl.handle.net/2066/232479
